PowerCHO® 2 Powder kit 10 L, CD with HEPES, Pluronic® F-68, without L-Glutamine, Phenol red, hypoxanthine or thymidine
PowerCHO® 2 Powder kit 50 L, CD with HEPES, Pluronic® F-68, without L-Glutamine, Phenol red, hypoxanthine or thymidine
PowerCHO® 2 Powder kit 500 L, CD with HEPES, Pluronic® F-68, without L-Glutamine, Phenol red, hypoxanthine or thymidine
Cryopreserved ampule of Diseased Human Lung Fibroblasts, Idiopathic Pulmonary Fibrosis (DHLF-IPF) containing ≥ 500,000 cells
Culture system containing B-ALITM Basal Media (00193516), B-ALITM Differentiation Media (00193517) and B-ALITM SingleQuotsTM Supplements (00193515) required for air-liquid interface differentiation of bronchial epithelial cells.
PowerCHO® 2 Powder kit 100 L, with HEPES, Pluronic® F-68, without L-Glutamine, Phenol red, hypoxanthine or thymidine
PowerCHO® 2 Basal Powder, 100 L, chemically defined
-
Inducible Cas9 T Cells: An Innovative Platform for Allogeneic CAR-T Cell GenerationPoster on inducible Cas9 T Cells
-
Synthego_Lonza_Protocol_Genome Editing of Resting T cellsTechnical Protocol on Genome Editing of Resting T cells for associated White Paper "Genome Editing of Resting T cells"
-
CAR T cells in Cancer TherapyA poster developed by Nature Reviews in conjunction with Lonza to present CAR T cells in cancer therapy. This poster demonstrates the recognition of tumor peptides by T cells, CAR T cell manufacturing, the types of chimeric antigen receptors and a timeline of CAR development over more than 30 years.
-
PBMC Based T Cell Proliferation AssayProtocol instructions
-
Instructions for Use – TheraPEAK® T-VIVO® Cell Culture Medium for Gamma Delta (γδ) T CellsInstructions for how to culture gamma delta (γδ) T Cells using TheraPEAK® T-VIVO® Cell Culture Medium
-
Instructions for Use - Dendritic Cell (DC) and T Cell Assay from Matched PBMCsProtocol for DC and T Cell Assay from Matched PBMCs
-
Case Study – Improving the Expansion of Patients' T CellsIn this serum-free media case study, learn how selection of memory T cells can aid in streamlining CAR-T therapies.
-
Synthego-Lonza Genome Editing of Resting T cellsCase Study on Genome Editing of Resting T cells
-
cGMP Kit T Optimization Protocol - Nucleofector™ 1/2 Device SeriescGMP Cell Line Nucleofector Kit T
-
CAR-T Cells – Latest Advances and Outstanding Challenges